Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 1099 • 2016 ACR/ARHP Annual Meeting
Synovial Exosomes Induce Osteoclast Differentiation in Rheumatoid arthritis
Ji Eun Song¹, Ji Hye Shin¹, Ki Won Moon², Se Hui Shon¹, Ji Soo Park³, Eun Bong Lee³, Yeong Wook Song^1,3 and Eun Young Lee³, ¹Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine or College of Pharmacy, Seoul National University, Seoul, Republic of Korea, Seoul, Korea, The Republic of, ²Department of Internal Medicine, Kangwon National University Hospital, Chuncheon, Republic of Korea, Chuncheon, Korea, The Republic of, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea, Seoul, Korea, The Republic of
Background/Purpose: Exosomes are small membrane vesicles (40-150 nm) of endocytic origin secreted by many types of cells and engage in cell-to-cell communication by transferring proteins,…
Abstract Number: 1956 • 2016 ACR/ARHP Annual Meeting
High Dose Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and Tumor Necrosis Factor Inhibitor Use Results in Less Radiographic Progression in Ankylosing Spondylitis – a Longitudinal Analysis
Lianne S. Gensler¹, John D. Reveille², MinJae Lee³, Thomas Learch⁴, Matthew Brown⁵, Mohammad H. Rahbar³, Michael Weisman⁶ and Michael Ward⁷, ¹Medicine/Rheumatology, UCSF, San Francisco, CA, ²Rheumatology, University of Texas-McGovern Medical School, Houston, TX, ³Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, University of Texas-McGovern Medical School, Houston, TX, ⁴Radiology, Cedars Sinai Medical Center, Los Angeles, CA, ⁵Queensland University of Technology, Brisbane, Australia, ⁶Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁷NIH/NIAMS, Bethesda, MD
Background/Purpose: Over the last decade, the disease modifying effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Tumor Necrosis Factor inhibitors (TNFi) have resulted in conflicting studies. …
Abstract Number: 2764 • 2016 ACR/ARHP Annual Meeting
Unhappiness Is Related to Worse Outcomes for Patients with Ankylosing Spondylitis and Increased Impairment in Daily Life Activities, Results from a Multinational Real-World Sample
Vibeke Strand¹, R Alten², Philip G. Conaghan³, Louise Huneault⁴, Emma Sullivan⁵, Stuart Blackburn⁵, Haijun Tian⁶, Kunal Gandhi⁶, Steffen Jugl⁷, Hedley Hamilton⁸ and Raj Mahapatra⁹, ¹Stanford University School of Medicine, Palo Alto, CA, ²Rheumazentrum Ruhrgebiet, Herne, Germany, ³NIHR-Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁴Novartis Pharma AG, Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland, ⁵Adelphi Real World, Manchester, United Kingdom, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁷Novartis Pharma AG, Basel, Switzerland, ⁸any-3 Ltd, London, United Kingdom, ⁹gplus, London, United Kingdom
Unhappiness is Related to Worse Outcomes for Patients with Ankylosing Spondylitis and Increased Impairment in Daily Life Activities, Results from a Multinational Real-World Sample Background/Purpose:…
Abstract Number: 700 • 2016 ACR/ARHP Annual Meeting
Incidence of Inflammatory Bowel Disease Events in Adalimumab (HUMIRA) Clinical Trials Across Indications
Jeffrey R. Curtis¹, Dirk Elewaut², Su Chen³, Maja Hojnik⁴, Navit Naveh⁵ and Jaclyn K. Anderson³, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²VIB Inflammation Research Center, University of Ghent, Ghent, Belgium, ³AbbVie Inc., North Chicago, IL, ⁴AbbVie, Ljubljana, Slovenia, ⁵AbbVie, Hod HaSharon, Israel
Background/Purpose: Adalimumab (ADA) is approved for treatment of Crohn’s disease (CD) and ulcerative colitis (UC); therefore, it is postulated that new onset or flare of…
Abstract Number: 1279 • 2016 ACR/ARHP Annual Meeting
Imaging of Ankylosing Spondylitis By [18f]Fluoride PET-CT to Assess Bone Formation Activity and to Monitor Anti-TNF Therapy
Stefan Bruijnen¹, Nicki Verweij², Leonie van Duivenvoorde³, Dominique Baeten⁴, Christiaan van Denderen⁵, Joost Bot⁶, Otto Hoekstra⁷, Pieter Raijmakers⁶, Irene van der Horst - Bruinsma⁸ and Conny van der Laken², ¹Dept. of Rheumtaology, Amsterdam Rheumatology and immunology Center - location VU University Medical Center, Amsterdam, The Netherlands, Amsterdam, Netherlands, ²Dept. of Rheumatology, Amsterdam Rheumatology and immunology Center - location VU University Medical Center, Amsterdam, The Netherlands, Amsterdam, Netherlands, ³Amsterdam Rheumatology and immunology Center, Academic Medical Center, Amsterdam, Netherlands, ⁴Amsterdam Rheumatology and immunology Center, Amsterdam, Netherlands, ⁵READE, Amsterdam Rheumatology and immunology Center, Reade, Amsterdam, Netherlands, ⁶Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, Netherlands, ⁷Nuclear medicine and PET research, VU University Medical Center, Amsterdam, Netherlands, ⁸Rheumatology, Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands
Background/Purpose: Bone formation is an important hallmark of ankylosing spondylitis (AS). Recently, we demonstrated that axial bone formation activity in AS patients can be visualized…
Abstract Number: 2003 • 2016 ACR/ARHP Annual Meeting
Validation of the ASAS Health Index: Results of a Multicenter International Study in 23 Countries
Uta Kiltz¹, Désirée van der Heijde², Annelies Boonen³, Jürgen Braun¹ and ASAS HI international validation study, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose: The ASAS Health Index (ASAS HI) was developed to measure functioning and health in patients with spondyloarthritis (SpA) aiming to better define the impact…
Abstract Number: 2777 • 2016 ACR/ARHP Annual Meeting
Is There a Difference in Clinical Features and Burden of Disease in Patients with Axial Spondyloarthritis with and without Extra-Articular Manifestations?
Kemal Erol¹, Gizem Cengiz¹, Kevser Gok¹, Gamze Kilic², Erkan Kilic³ and Salih Ozgocmen¹, ¹Dept.PRM, Erciyes University, Faculty of Medicine, Division of Rheumatology, Kayseri, Turkey, ²Afyon Kocatepe University, Faculty of Medicine, Dept.PRM, Afyon, Turkey, ³Afyonkarahisar Kocatepe State Hospital, Division of Rheumatology, Afyon, Turkey
Background/Purpose: Spondyloarthropathies include a group of disease which have similar clinical, radiographic and genetic features. Uveitis, psoriasis (PsO) and inflammatory bowel disease (IBD) are common…
Abstract Number: 61 • 2016 ACR/ARHP Annual Meeting
Killer Immunoglobulin-like Receptors Are Associated with Ankylosing Spondylitis
Aimee Hanson¹, International Genetics of Ankylosing Spondylitis Consortium (IGAS)², Kim-Anh Lê Cao³, Tony J. Kenna⁴ and Matthew A. Brown², ¹The University of Queensland Diamantina Institute, Translational Research Instiute, Brisbane, Australia, Brisbane, Australia, ²Translational Genomics Group, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Australia, Brisbane, Australia, ³Translational Research Instiute, The University of Queensland Diamantina Institute, Brisbane, Australia, ⁴Translational Research Institute, Translational Genomics Group, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia
Background/Purpose: Killer immunoglobulin-like receptors (KIRs) are expressed predominantly on the surface of natural killer (NK) cells and some T-cells and are important in regulating the…
Abstract Number: 68 • 2016 ACR/ARHP Annual Meeting
Epigenetic and Expression Analysis of Ankylosing Spondylitis Association Loci Point to Key Cell Types Driving Disease
Zhixiu Li¹, Katelin Haynes², Gethin P. Thomas³, Tony J. Kenna¹, Paul Leo¹ and Matthew A. Brown¹, ¹Translational Genomics Group, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Australia, Brisbane, Australia, ²University of Queensland Diamantina Institute, Brisbane, Australia, Brisbane, Australia, ³Research Office, Charles Sturt University, Wagga, Australia, Wagga, Australia
Background/Purpose: Susceptibility to ankylosing spondylitis (AS) is primarily genetic; thus far 113 susceptibility variants for AS have been identified. However, most of the AS associated…
Abstract Number: 713 • 2016 ACR/ARHP Annual Meeting
Predictors of Treatment Retention Among Patients with Rheumatoid Arthritis or Ankylosing Spondylitis Treated with Remicade® (Infliximab) for Long-Term in Canadian Real-World
Michael Starr¹, Edward Keystone², Rafat Faraawi³, Louis Bessette⁴, Boulos Haraoui⁵, Wojciech Olszynski⁶, John Kelsall⁷, Raman Joshi⁸, Andrew Chow⁹, Algis Jovaisas¹⁰, J Carter Thorne¹¹, Emmanouil Rampakakis¹², Eliofotisti Psaradellis¹³, Marilise Marrache¹⁴, Brendan Osborne¹⁵, Karina Maslova¹⁶, Francois Nantel¹⁷, Allen J Lehman¹⁶ and Cathy Tkaczyk¹⁵, ¹Rheumatology, Mcgill University, Pointe-Claire,, QC, Canada, ²Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³McMaster University, Hamilton, ON, Canada, ⁴Rheumatology, CHUL de Quebec, Quebec, QC, Canada, ⁵Centre hospitalier de l'Université de Montréal, Montreal, QC, Canada, ⁶103 Midtown Professional Center, Rheumatology Associates of Saskatoon, Saskatoon, SK, Canada, ⁷Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁸William Osler Health Centre-Brampton Civic Hospital, Brampton, ON, Canada, ⁹Credit Valley Rheumatology, Mississauga, ON, Canada, ¹⁰Capital North Therapeutics & Research, Ottawa, ON, Canada, ¹¹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²JSS Medical Research, St-Laurent, QC, Canada, ¹³JSS Medical Research, Montreal, QC, Canada, ¹⁴Medical Affairs, Janssen Inc, Toronto, ON, Canada, ¹⁵Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹⁶Janssen Inc., Toronto, ON, Canada, ¹⁷19 Green belt Dr, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Remission has become a target to achieve in rheumatic diseases and it also could be linked to treatment retention. The aim of this analysis…
Abstract Number: 1281 • 2016 ACR/ARHP Annual Meeting
Feasibility and Reliability of the Spondyloarthritis Research Consortium of Canada Sacroiliac Joint Inflammation Score for Children with Spondyloarthritis
Nancy A. Chauvin¹, Walter P. Maksymowych^2,3, Robert G. Lambert⁴, Jacob Jaremko⁵, David M. Biko¹, Timothy G. Brandon⁶, Joel Paschke² and Pamela F. Weiss^7,8, ¹Radiology, Children's Hospital of Philadelphia, Philadelphia, PA, ²CaRE Arthritis, Edmonton, AB, Canada, ³Medicine, University of Alberta, Edmonton, AB, Canada, ⁴Radiology, University of Alberta, Edmonton, AB, Canada, ⁵Radiology, Radiology, University of Alberta, Edmonton, AB, Canada, ⁶Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, ⁷Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ⁸Division of Rheumatology, Center for Pediatric Clincial Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: We lack a method to quantify severity of inflammation in the pediatric sacroiliac joint. We evaluated the reliability and construct validity of the Spondyloarthritis…
Abstract Number: 2006 • 2016 ACR/ARHP Annual Meeting
Tuberculosis Incidence in Ankylosing Spondylitis, Psoriatic Arthritis, and Other Spondyloarthropathies in Sweden: A Population-Based Cohort Study
Mirjam K. de Vries¹, Elizabeth V. Arkema¹, Jerker Jonsson², Judith Bruchfeld³, Lennart TH Jacobsson⁴ and Johan Askling^1,5, ¹Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ²Infectious Diseases Unit, Karolinska University Hospital, The Public Health Agency of Sweden, Stockholm, Sweden, ³Department of Medicine, Infectious Diseases Unit, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, ⁵Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Patients with rheumatoid arthritis (RA) are at a well-documented increased risk of tuberculosis (TB) compared to the general population, both with and without treatment…
Abstract Number: 3038 • 2016 ACR/ARHP Annual Meeting
Enumeration and Preliminary Characterisation of Peri-Entheseal Bone Type 3 Innate Lymphoid Cells
Richard Cuthbert¹, Yasser El-Sherbiny¹, Evangelos M. Fragkakis¹, Robert Dunsmuir², Helena Marzo-Ortega³, Elena Jones¹ and Dennis McGonagle¹, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²Department of Spinal Surgery, National Health Service, Leeds, United Kingdom, ³NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals and University of Leeds, Leeds, United Kingdom
Background/Purpose: In an IL-23 overexpression animal model of spondyloarthropathy (SpA), primary entheseal disease is driven by innate like lymphocytes at peripheral and spinal enthesis with…
Abstract Number: 80 • 2016 ACR/ARHP Annual Meeting
Impact of a Patient Support Program on Abandonment of Adalimumab Treatment Initiation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis
Philip Mease¹, Manish Mittal², Martha Skup², Matthew Davis³, Arijit Ganguli², Scott Johnson³ and Michael Schiff⁴, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²AbbVie Inc., North Chicago, IL, ³Medicus Economics, LLC, Milton, MA, ⁴University of Colorado, Greenwood Village, CO
Background/Purpose: Treatment abandonment (failure to start therapy after prescription) is common among patients (pts) prescribed specialty pharmaceuticals. AbbVie offers a pt support program (PSP) for…
Abstract Number: 714 • 2016 ACR/ARHP Annual Meeting
Functional Relevance of Structural Damage in the Sacroiliac Joints in Patients with Axial Spondyloarthritis – Results from the German Spondyloarthritis Inception Cohort
Mikhail Protopopov¹, Hildrun Haibel¹, Jürgen Braun², Martin Rudwaleit³, Joachim Sieper¹ and Denis Poddubnyy¹, ¹Charité Medical University, Berlin, Germany, ²Rheumazentrum Ruhrgebiet, Herne, Germany, ³Klinikum Bielefeld Rosenhöhe, Bielefeld, Germany
Background/Purpose: To analyze the association between the presence of structural damage in the sacroiliac joints and physical function / spinal mobility in patients with axial…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].